The diabetogenic variant of encephalomyocarditis virus (EMC-D) induces a diabeteslike syndrome in certain strains of mice. A study was done to determine if virus-induced diabetes could be prevented by interferon (IFN). It was found that the production of diabetes by EMC-D was blocked by either IF", or a variety of IFN-inducers in SWR/J, but not ICR Swiss mice. The replication of EMC-D in cell culture was inhibited by IFN,. It is concluded that the response of pancreatic beta cells to the protective effect of IFN, is probably under genetic control.
The diabetogenic strain of encephalomyocarditis virus (D virus) was propagated in several continuous cell lines. Each virus stock was tested for its ability to produce diabetes in mice and induce L-cell interferon (IFN-beta). The effect of insulin on virus replication and IFN-beta induction was also determined. It was found that the severity of the diabetes and the amount of IFN-beta produced was dependent on the cell line used for virus propagation. Virus synthesis was augmented and IFN-beta production was altered in insulin-treated cell cultures. It is concluded that D virus either consists of more than one virus or that its diabetes and IFN-beta inducing characteristics are unstable.
Adult male ICR Swiss mice develop diabetes mellitus when infected with the D variant of encephalomyocarditis virus. It was determined that the disease syndrome caused by the virus in this mouse strain is dependent upon the age of the animals. Mice younger than 7 weeks developed lethal encephalitis, whereas those past this age developed diabetes. The susceptibility of young mice to the diabetogenic effects of encephalomyocarditis virus was enhanced by testosterone.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.